Interim report April – June 2026
Second quarter in brief · Net sales amounted to 14.0 MSEK (12.4), which means an increase in sales of 13 percent. · Operating profit amounted to -6.5 MSEK (-8.6). · Net profit for the period amounted to -6.1 MSEK (-10.4). · Earnings per share before dilution amounted to -0.06 SEK (-0.16). · Cash flow from operating activities amounted to -2.6 MSEK (0.5). Cash and cash equivalents amounted at the end of the period to 28.3 MSEK (19.4). First six months in brief · Net sales for the first half year amounted to 27.1 MSEK (26.6), which means an increase in sales of 2 percent. · Operating profit amounted to 12.7 MSEK (-18.9). · Profit for the period amounted to -12.3 MSEK (-23.7). · Earnings per share before dilution amounted to -0.14 SEK (-0.48). · Cash flow from operating activities amounted to -6.2 MSEK (2.1). Cash and cash equivalents amounted at the end of the period to 28.3 MSEK (19.4). Significant events during the second quarter In April, cMRI ARIA received regulatory approval in the UK and Switzerland. Significant events during the first six months 9[th] of January, an extraordinary general meeting was held at which the Rights Issue was approved. 4[th] February, the outcome of the rights issue was announced, which was subscribed to 98.6% with and without subscription rights, and the remaining 1.4% through a guarantee commitment. In April, cMRI ARIA received regulatory approval in the UK and Switzerland. Significant events after the end of the quarter Nothing to report.